 |
27 Diseases |  |
27 Trials |
|
27 Trials |  |
3795 News |  |
| «12...1718192021222324252627...4546» |
- || dimethyl fumarate / Generic mfg.
Clinical, Journal: COVID-19 in multiple sclerosis patients treated with dimethyl fumarate. (Pubmed Central) - Aug 18, 2021
No abstract available
- ||| glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
3. I was taking Copaxone, but getting my skin damaged. My doc suggested Tecfidera. But I was afraid of acid reflux. Before starting the new dmt I put myself in a really strict gluten free and diary free diet. Took probiotics. When I was just diagnosed I did the Swank diet. (Twitter) - Aug 17, 2021
- | dimethyl fumarate / Generic mfg.
Journal: The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis. (Pubmed Central) - Aug 15, 2021
HTRA1 is a promising CSF biomarker for MS correlating with disease- and disability progression. Most cell species of the normal and diseased CNS express HTRA1 and the expression pattern could reflect pathological processes involved in MS pathogenesis.
- |||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Enrollment open: STHENOS: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (clinicaltrials.gov) - Aug 13, 2021
P3, N=236, Recruiting, Sponsor: Novartis Pharmaceuticals
Most cell species of the normal and diseased CNS express HTRA1 and the expression pattern could reflect pathological processes involved in MS pathogenesis. Not yet recruiting --> Recruiting
- dimethyl fumarate / Generic mfg.
Repurposing of Kreb’s cycle-derived metabolites as antiviral agents and oncolytic virus sensitizers (Room: B313b - B314) - Aug 13, 2021 - Abstract #ACSFall2021ACS_Fall_3243;
Pre-treatment of 4T1 aggressive murine breast cancer cells and 786-O human renal carcinoma cells with 4-OI markedly reduced the replicative properties of HSV-1 g34.5 and Vaccinia Virus JX-594 but dramatically enhanced VSVDM51 infectivity and oncolytic activity in vitro. Altogether, our data suggest that endogenous metabolites are plausible broad-spectrum anti-viral agents that could be used in the treatment of existing or newly emerging viral infections but at the same time can also serve the purpose of virus boosters in oncolytic virotherapy treatment of cancer.
- || dimethyl fumarate / Generic mfg.
Clinical, Journal: Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis. (Pubmed Central) - Aug 13, 2021
A higher lymphocyte count drop at six months is related to better outcomes in DMF-treated patients. A careful ALC monitoring should be pursued up to 24 months of treatment.
- | dimethyl fumarate / Generic mfg.
Journal: Nrf2 protects against seawater drowning-induced acute lung injury via inhibiting ferroptosis. (Pubmed Central) - Aug 12, 2021
These results suggested that Nrf2 can inhibit ferroptosis and therefore alleviate ALI induced by seawater drowning. The effectiveness of ferroptosis inhibition by Nrf2 provides a novel therapeutic target for seawater drowning-induced ALI.
- | dimethyl fumarate / Generic mfg.
Journal: First-ever treatment in multiple sclerosis. (Pubmed Central) - Aug 8, 2021
Our findings support efficacy and tolerance of both drugs in early-treated treatment-naive MS patients, arguing in favour of efficient early immunomodulation in MS patients. Both drugs significantly reduced the incidence of new relapses and Gd-enhancing lesions on treatment with FTY being more frequently prescribed than DMF, especially in patients with evidence of higher clinical disease activity.
- || dimethyl fumarate / Generic mfg.
Clinical, Observational data, Journal: Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study. (Pubmed Central) - Aug 7, 2021
Both drugs significantly reduced the incidence of new relapses and Gd-enhancing lesions on treatment with FTY being more frequently prescribed than DMF, especially in patients with evidence of higher clinical disease activity. The results of our study emphasize the importance of education and communication campaigns addressed both to healthcare providers and patients with MS, especially considering that MS patients are currently receiving COVID-19 vaccinations.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] PAEDIATRIC MS (Main Topic A) - Aug 6, 2021 - Abstract #WCN2021WCN_495;
Limited information is available from retrospective studies regarding the safety and efficacy of these drugs in children except for fingolimod and teriflunomide that were studied in a randomized controlled trials in patients 10-17 years of age. Several ongoing trials are investigating the use of dimethyl fumarate and ocrelizumab in pediatric MS and will aid future treatment decisions including short-term safety information.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COMPARATIVE EFFECTIVENESS OF EARLY INTENSIVE OR ESCALATION TREATMENT STRATEGIES ON LONG TERM DISABILITY TRAJECTORIES IN RELAPSING MULTIPLE SCLEROSIS PATIENTS (Free Communication C) - Aug 6, 2021 - Abstract #WCN2021WCN_228;
EIT group included patients who received, as first DMT natalizumab, fingolimod, alemtuzumab, ocrelizumab, cladribine, mitoxantrone,. ESC group patients received the high efficacy DMT after ≥1 year of injectables DMTs, azathioprine, teriflunomide or dimethylfumarate treatment... Our findings indicate a higher effectiveness of EIT than ESC strategy in slowing disability worsening over time.
- | dimethyl fumarate / Generic mfg.
Retrospective data, Journal: A retrospective analysis of changes in lymphocyte levels in patients with multiple sclerosis during and after Tecfidera® treatment. (Pubmed Central) - Aug 5, 2021
CD4:CD8 T cell ratio was the measurement that had the highest rate of change in response to DMF initiation and discontinuation. CD8+ T cell count and CD4:CD8 T cell ratio may be a more sensitive measurement of the immune landscape of patients with MS on DMF.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] The radiologically isolated syndrome (RIS), is it already MS? (Stream 8 Educational Sessions) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1295;
The recommendation is not to treat off label these subjects as 2 phases 3 studies are ongoing in the USA and Europe with dimethyl fumarate and teriflunomide. A phase IV with ocrelizumab is starting in the USA.
- opicinumab (BIIB033) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Efficacy and safety of opicinumab in participants with relapsing multiple sclerosis: a randomized, placebo-controlled, Phase 2 trial (AFFINITY Part 1) (Stream 7 Therapy / Global views) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1287;
P2
Learnings from the AFFINITY study and additional data analyses may inform the design of future remyelination trials. Supported by: Biogen
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Dimethyl fumarate alters gut microbiota metabolism in multiple sclerosis (Stream 3 Pathogenesis) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1246;
We show that metabolic properties of DMF reach beyond immune cells and relevantly alter the gut microbiome. Further analysis will distinguish how this impact on gut microbiota determines side effects and shapes therapeutic response to DMF.
- evobrutinib (M2951) / EMD Serono
[VIRTUAL] Evobrutinib significantly reduces relapses and magnetic resonance imaging outcomes in patients with multiple sclerosis: association with baseline neurofilament light chain levels (Stream 7 Therapy / Global views) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1205;
P2
The data indicate that higher doses of evobrutinib reduce MRI activity, regardless of baseline NfL levels, and significantly reduce the proportion of patients with relapses versus placebo/low doses, in the high blood NfL level group. They also further support the value of blood NfL levels as a prognostic marker of future disease activity.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Opportunistic infections under disease-modifying therapies (Stream 9 Educational Sessions) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1170;
Its risk is the highest in natalizumab-treated MS patients, followed by fingolimod, and then dimethyl-fumarate...An emphasis will be put on the increasingly-recognized role of ageing in favoring the occurrence of these opportunistic infections, independently of the underlying DMT. This is a real concern considering that more and more ageing MS patients are under DMTs.
- Zinbryta (daclizumab) / Biogen, AbbVie
[VIRTUAL] Blueteq data : EDSS scores in patients on disease modifying therapy at a single centre (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1068;
These results present real world data on the use of EDSS to monitor response to treatment. The Blueteq data is currently limited by a short length of follow up but has potential value over time in tracking mean change in EDSS on each DMT.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Long-term immune-related adverse events after alemtuzumab (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1065;
The autoimmune adverse events are probably related to immune dysregulation due to a differential lymphocyte repopulation following alemtuzumab. Autoimmune adverse events may be frequent, and it would be recommended to monitor its appearance in order to diagnose and treat them.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Reconstitution of lymphocytes following discontinuation of dimethyl fumarate (DMF) due to lymphopenia in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1063;
Data from the Swedish IMSE 5 study suggest that a lymphocyte reconstitution occurs within 13 to 16 weeks following the discontinuation of DMF. However, larger datasets will be needed to verify this finding and also to determine the possible impact of any newly started therapy.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study “immunomodulation and multiple sclerosis epidemiology 10” (IMSE 10) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1062;
CladT treatment demonstrates clinical stability in patients treated ≥ 12 months. However, continued follow-up is needed to assess the effectiveness and safety of CladT over a longer time to assess if these results sustain after the final treatment course has been administered.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease-modifying treatment patterns of patients with multiple sclerosis and newly treated with cladribine tablets or fingolimod: an interim analysis of the CLARION study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1061;
The most common agents used in the past were interferon beta-1a, DMF, teriflunomide and GA. Teriflunomide was the most common last DMT prior to initiation of CladT or fingolimod.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 Study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1058;
P3
The low rate of treatment discontinuation over the 2-year period suggests DRF is a well-tolerated treatment option for RRMS. At 2 years, clinical and radiological measures were reduced from baseline, supporting DRF as an effective treatment option.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 5 years in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1054;
However; due to the high discontinuation rate there is an unavoidable selection bias. Continued follow up is needed to assess the effectiveness and safety of DMF over longer time periods in a real world setting.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] The influence of disease modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1047;
BCDT further showed a time-dependent decrease of IgG and IgM. Hypogammaglobulinemia may result in a higher susceptibility to infectious diseases.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Disease activity and patient-reported outcomes in patients with multiple sclerosis switching from first-line platform therapies to dimethyl fumarate (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1037;
P=N/A
Overall, results suggest that DMF is an effective treatment option for patients with RRMS previously treated with injectable therapies or teriflunomide, regardless of the reasons that led to the switch from the previous first-line treatment. Supported by: Biogen
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world patient-reported outcomes in RRMS patients transitioning to alemtuzumab: results from the PRO-ACT study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1024;
Significant improvements in employment and household productivity were seen after switching, which may reflect a reduction in the burden that MS imposes on patients with employment and household responsibilities. Alemtuzumab safety was consistent with the pivotal studies.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate: a longitudinal study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_924;
The ECS is dysregulated in MS patients, as shown by the lower levels of 2-AG and PEA. DMF treatment modulates the levels of at least 3 of the endocannabinoids (2-AG, OEA and PEA), and this modulation fluctuates depending on the endocannabinoid and treatment time, and it seems not to be associated with clinical response to DMF.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Comparing the impact of dose titration on gastrointestinal tolerability: diroximel fumarate versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_916;
GI AE incidence/severity were highest with DMF in Weeks 3 and 4, after the 1-week titration. This is consistent with DMF real-world experience, where some HCPs have employed extended titration schedules to improve GI tolerability.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Flushing and flushing-related adverse events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis: results from the Phase 3 EVOLVE-MS-2 Study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_897;
P3
Although in DRF-treated patients flushing occurred in fewer patients, the incidence of flushing for DRF was generally within the expected range when compared to rates reported in DMF controlled clinical trials. The clinical meaningfulness of the observed changes is uncertain and additional real-world studies are necessary.
- Mayzent (siponimod) / Novartis
[VIRTUAL] Safety and tolerability of conversion to siponimod with and without titration in patients with advancing forms of relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_896;
P3
Immediate conversion from other DMTs to siponimod had an acceptable safety and tolerability profile, with no unexpected findings. There was no evidence of a meaningful reduction in heart rate when initiating siponimod in the overall group or in subgroups stratified by prior DMTs, including subjects transitioning from fingolimod to siponimod without dose titration.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Factors associated with dimethyl fumarate induced lymphopenia in a rural multiple sclerosis cohort (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_892;
There was no evidence of a meaningful reduction in heart rate when initiating siponimod in the overall group or in subgroups stratified by prior DMTs, including subjects transitioning from fingolimod to siponimod without dose titration. Our study aims to identify factors associated with DMF induced lymphopenia, evaluate risk factors for patients and build a prediction model to provide more information for doctors to estimate patients’ benefits/risks for MS patients
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A retrospective review of COVID spike protein antibody development following COVID-19 vaccination in MS patients on disease modifying drugs (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_889;
This study is limited in retrospective design, small un-balanced groups, and lack of longitudinal data. We cannot exclude the possibility of a more robust delayed humoral response.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Demographic features and clinical course of pediatric-onset MS patients on newer disease-modifying treatments (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_878;
POMS patients who initiated treatment between 10- <18 years with dimethyl fumarate, fingolimod, natalizumab, rituximab or ocrelizumab were included and analyzed as individual cohorts... Though limited by relatively short treatment duration with the index DMTs, our data suggest clinical and MRI benefit in a large number of POMS patients, which can be used to guide future studies in this population.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_871;
In addition, we found a superior effect of natalizumab on reducing the rate of disability worsening and improving disability. This study demonstrates the capacity of ATE and ATT MSM to evaluate the effectiveness of multiple MS therapies simultaneously.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease-modifying therapy effect on COVID-19 vaccine response in multiple sclerosis patients: data from two New York State Multiple Sclerosis Consortium centers (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_854;
MS patients treated with B-cell depleting medications and S1P modulators have significantly lower seroconversion after COVID-19 vaccination when compared to DMT-naïve patients and other DMT groups. Future studies should determine the risk of severe clinical outcomes in vaccinated patients with no evidence of seroconversion.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Colombia (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_838;
No significant differences were observed by sex and treatment type in prognosis and mortality from COVID-19. However, we suggested to carry out robust sample studies to identify the main complicating factors and severity.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
[VIRTUAL] Multiple sclerosis patients initiating ofatumumab in the real-world: 6 months data (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_795;
Most patients newly initiated ofatumumab had no treatment in the prior year. Understanding patient profile, prior DMT use in the real-world may help stakeholders guide treatment decisions.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Cladribine in a real world setting. The real patients (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_790;
23 patients switch from teriflunomide, 16 from dimethylfumarate, 14 from fingolimod, 22 from injectables, 1 from alemtuzumab... In the real world cladribine has proved to be effective, safe and very well tolerated.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_788;
In the real world cladribine has proved to be effective, safe and very well tolerated. Our findings suggests that dimethyl fumarate has a lower risk of discontinuation because of treatment failure among both treatment-experienced and treatment-naive patients.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Relapse during the washout period predicts time to relapse after switching to cladribine (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_781;
Washout durations shorter than two months were associated with fewer washout relapses. Prospective studies are needed to assess if washout period reduction can modify relapse outcomes when switching to cladribine.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Effectiveness of relapsing multiple sclerosis patients switching to teriflunomide following disease progression in a real-world setting (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_779;
Following switch to teriflunomide, patients demonstrated numerical reductions in mean EDSS, and most demonstrated stability or improvement in ARR, MRI lesions, and use of ambulatory aids. Long-term assessment of this cohort may aid in understanding the impact of teriflunomide on clinical outcomes in disease progressing RMS patients.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] MASTER-2 trial: cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results) (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_772;
P=N/A
MASTER-2 will report real-world data on the effects of CladT3.5 after a suboptimal response to oral/infusion DMT. Baseline analysis is ongoing and results from a data cut in July 2021 will be shown in the presentation.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Early data suggests diroximel fumarate has high rates of real-world adherence and persistence (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_771;
The finding that higher persistence is seen with newer DMTs vs older DMTs should be explored in future matched comparisons. These data support DRF as a well-tolerated fumarate.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Therapeutic management of relapsing-remitting multiple sclerosis in France in the recent era (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_764;
Our results suggest that moderately effective first-line DMTs do not always allow an effective control of the disease. Therapeutic management is a key element of current MS care (when switch and to what).
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Multiple sclerosis patients treated with diroximel fumarate over 1 year in the real-world setting have high rates of persistence and adherence (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_759;
Adherence was also high in the prior DMF subgroup. The most common reason for discontinuing prior DMF was GI AEs; most of the prior DMF pts were able to remain on DRF, further supporting improved GI tolerability with DRF.
- Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Anti-Spike IgG after BNT162b2 vaccine in a group of multiple sclerosis patients from an exploratory case-control study in Italy (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_757;
In our study, most MS patients produce a serological response to BNT162b2 similar to non-MS controls; however, at-risk DMTs resulted in reduced anti-Spike levels and one ocrelizumab-treated patient did not respond. These observations should be better investigated and replicated in larger studies to support clinical decision in COVID-19 vaccine management.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Effectiveness and safety of early high-efficacy vs. escalation therapy in relapsing-remitting multiple sclerosis in Argentina (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_748;
Our study shows that EHE therapies prevent disease progression, relapses and new MRI lesions and demonstrated no increased risk of specific adverse events when compared to ES therapy. This data should be considered when selecting a specific treatment for MS patients.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_740;
Objective: To compare the clinical outcomes in patients on DMF and TFL in a real-world setting, where both drugs are licensed as a first-line disease modifying therapy (DMT) for RRMS... Analysis of real-world data showed that in RRMS, DMF treatment was associated with more favorable clinical outcomes compared to TFL.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Cost-effectiveness of ofatumumab in comparison with other disease modifying therapies and best supportive care for the treatment of relapsing-remitting multiple sclerosis in Canada (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_732;
Considering first-line therapies, ofatumumab was dominant (more efficacy, lower costs) over teriflunomide, interferons, dimethyl fumarate, and ocrelizumab, and resulted in incremental cost-utility ratios (ICURs) of $24,177 Canadian dollars per quality-adjusted life-years (QALYs) gained versus glatiramer acetate and $28,034 versus BSC... In Canada, ofatumumab is cost effective against all comparators and dominant compared to all currently approved and reimbursed first-line DMTs for the treatment of patients with RRMS, except glatiramer acetate.